GLP-1 weight-loss injections: What do we actually know about the long-term risks, what happens when people stop, and the implications for the UK?
There is considerable enthusiasm about medications such as Wegovy (semaglutide) and Mounjaro (tirzepatide), and understandably so. Clinical trials have demonstrated substantial weight loss and, in some patient groups, significant improvements in cardiovascular and metabolic health.
However, I think it's important that discussions include the limitations of the evidence, particularly when these medications may need to be taken for many years.
1. We still don't know the consequences of taking newer GLP-1 treatments for decades.
Although GLP-1 medications have been used to treat diabetes for approximately 20 years, the newer obesity treatments, higher doses and widespread use in different populations are relatively recent.
We have encouraging evidence extending approximately three to four years for some treatments, but not the 10-, 20- or 30-year evidence that would help establish the consequences of lifelong treatment.
Established or recognised risks include:
- Gastrointestinal problems, including nausea, vomiting, constipation and diarrhoea. Severe cases can lead to dehydration and hospitalisation.
- Gallbladder problems, including gallstones.
- Acute pancreatitis, which is uncommon but can be severe.
- Loss of lean body mass alongside fat during weight reduction, raising questions about muscle preservation and longer-term physical function.
- Potential nutritional inadequacy when appetite suppression results in insufficient dietary intake.
- A very rare but serious eye condition, NAION, associated specifically with semaglutide, which can cause sudden visual loss.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has strengthened warnings about pancreatitis, including rare reports of fatal cases.
Importantly, none of this means these medications are generally unsafe. It means the benefits and risks must be assessed for the individual, and some long-term questions remain unresolved.
2. What happens when people stop taking them?
This is perhaps one of the most important findings from the research.
A systematic review and meta-analysis published in the
BMJ in 2026 examined weight regain following discontinuation of weight-management medications.
For newer treatments, including semaglutide and tirzepatide, researchers estimated average weight regain of approximately
0.8 kg per month after stopping.
They projected that participants could return to their original weight approximately
1.5 years after discontinuation.
This was a statistical projection, not a finding that everyone had regained all their weight after 18 months. The available follow-up evidence was limited.
Nevertheless, the findings are consistent with randomised withdrawal trials demonstrating substantial weight regain after treatment ends.
This raises an obvious question: if weight maintenance frequently requires ongoing medication, how will long-term treatment be funded, particularly for people who cannot afford private prescriptions indefinitely?
3. The World Health Organization has raised concerns about health inequalities.
In its 2025 guidance, the WHO conditionally recommended long-term GLP-1 treatment for adults living with obesity.
The recommendation was conditional partly because of limited long-term evidence, high costs, health-system capacity and concerns about equitable access.
The WHO warned that high prices, limited manufacturing capacity and unequal access could create a situation in which people with greater financial resources receive effective treatment while others are excluded.
This is particularly concerning because obesity is strongly associated with socioeconomic deprivation.
We therefore risk a situation in which people experiencing some of the greatest obesity-related health burdens have the least access to newer treatments.
The WHO also emphasised that medication alone cannot solve the obesity epidemic. Wider action addressing food environments, socioeconomic conditions and the commercial determinants of health remains necessary.
4. Why the UK cannot simply be compared with the United States
I frequently see arguments based on American prescribing patterns, insurance arrangements, drug prices and expectations about future availability.
But the UK operates within a fundamentally different healthcare and medicines-funding system.
In England, NHS access to obesity medications is governed by NICE recommendations, clinical eligibility criteria, NHS commissioning arrangements and available resources.
For example, Mounjaro is being introduced through a phased NHS rollout, prioritising patients with the greatest clinical need. Wider eligibility does not mean immediate access for everyone who meets the eventual criteria.
In the US, access is heavily influenced by private insurance arrangements, employer coverage, public insurance programmes and individual ability to pay.
These are different systems with different mechanisms for determining who receives treatment and who pays.
Even if generic or cheaper alternatives become available,
lower manufacturing costs do not automatically translate into immediate, unrestricted NHS prescribing.
NICE must consider clinical effectiveness and cost-effectiveness, while the NHS must fund the medication, provide appropriate monitoring and manage demand alongside other healthcare priorities.
We also need to remember that healthcare arrangements differ across the UK's four nations.
5. The bigger question
I don't think this debate needs to become a choice between celebrating GLP-1 medications or dismissing them.
They represent a significant development in obesity treatment, and the evidence for their effectiveness is substantial.
But effectiveness, long-term safety, affordability, sustainability and equitable access are different questions.
If large numbers of people need treatment for many years to maintain weight loss, that has major implications for patients, public finances and the organisation of healthcare.
And if access is determined increasingly by the ability to pay, we could see existing health inequalities widen.
These are legitimate public-health concerns, not arguments against people using medication.
The challenge is to make sure enthusiasm about an effective treatment doesn't get ahead of the evidence or distract from the wider conditions contributing to obesity in the first place.
Sources
- World Health Organization (2025), WHO Guideline on GLP-1 Therapies for Obesity in Adults, JAMA. https://doi.org/10.1001/jama.2025.24288
-
BMJ (2026), Weight regain after cessation of medication for weight management: systematic review and meta-analysis. https://www.bmj.com/content/392/bmj-2025-085304
- MHRA, GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis. https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-and-dual-glp-1-slash-gip-receptor-agonists-strengthened-warnings-on-acute-pancreatitis-including-necrotising-and-fatal-cases
- MHRA, Semaglutide: risk of non-arteritic anterior ischaemic optic neuropathy (NAION). https://www.gov.uk/drug-safety-update/semaglutide-wegovy-ozempic-and-rybelsus-risk-of-non-arteritic-anterior-ischemic-optic-neuropathy-naion
- NICE, Tirzepatide for managing overweight and obesity, Technology Appraisal TA1026. https://www.nice.org.uk/guidance/ta1026